Fevertree extends share buyback by £30m as transition to Molson Coors progresses

Fevertree Drinks reported interim results largely in line with expectations, with stable revenue at £172.2 million and adjusted EBITDA up 1% to £18.4 million, despite a 15% drop in profit before tax. The firm significantly boosted cash to £130.0 million, enabling a £30 million extension to its share buyback program and a 2% dividend increase. Management highlighted the successful progression of the Molson Coors North American distribution transition, which is driving strong US retail sales, alongside robust UK off-trade performance and product diversification, with non-tonic lines now 45% of revenue. The company maintains confidence in its full-year outlook.

Analysis

Fevertree Drinks' interim results signal a period of strategic execution and capital discipline, with performance largely meeting market expectations. While headline revenue remained stable at £172.2 million (a 2% increase at constant currency) and adjusted EBITDA grew a modest 1% to £18.4 million, a notable 15% decline in profit before tax to £11.2 million points to underlying cost pressures. The most significant development is the balance sheet fortification, with cash nearly doubling to £130.0 million, bolstered by inflows from the new North American distribution partnership with Molson Coors. This enhanced liquidity underpins the firm's shareholder return policy, evidenced by a 2% dividend increase to 5.97p per share and a £30 million extension of its share buyback program into 2026. Operationally, the transition to the Molson Coors network is reportedly progressing well, maintaining strong US retail sales momentum. This progress in the key US market, combined with robust UK off-trade performance and successful product diversification—with non-tonic products now accounting for 45% of revenue—is offsetting weakness in the subdued UK on-trade channel. Management's reaffirmation of the full-year outlook provides a layer of confidence, suggesting operational headwinds are currently manageable.

Key Decisions for Investors

• The significant increase in cash to £130.0 million and the subsequent £30 million buyback extension signal strong management confidence and provide a valuation floor, suggesting investors should view the stable top-line as a solid base for future growth driven by the US partnership.
• Investors should closely monitor the evolution of pre-tax profit margins, as the 15% decline highlights a key risk area that could cap upside even if revenue growth accelerates in the second half.
• The successful diversification, with non-tonic products now comprising 45% of revenue, warrants a re-evaluation of Fevertree's growth narrative beyond the premium mixer category, potentially justifying a higher long-term multiple if the trend continues.
• Continued positive commentary on the Molson Coors integration should be treated as a primary catalyst, with any signs of friction or unexpected costs during the transition representing a significant red flag for the North American growth thesis.